Jim Walsh

Jim Walsh has extensive experience in pharmacovigilance and drug safety, currently serving as Manager of Pharmacovigilance Operations at ImmunoGen, Inc. since March 2022. Prior to this role, Jim worked at Alkermes for over a decade as a Senior Drug Safety Specialist, focusing on the triage and quality review of adverse events from postmarketing and Investigator Initiated Trials, while also ensuring standards for coding and reporting of serious adverse events. Previous positions include Quality Lead of Pharmacovigilance at Vertex Pharmaceuticals, where Jim developed a regulatory intelligence strategy for the company's first approved drug, and Drug Safety Data Specialist at BiogenIdec, managing quality reviews for clinical trials across multiple therapeutic areas. Jim holds a Bachelor of Science degree in Exercise Physiology from UMass Boston.